Ernexa Therapeutics Completes ERNA-101 Process Development, Begins GMP Manufacturing
ERNA•Ernexa completed process development for its lead cell therapy ERNA-101 and has transitioned into GMP manufacturing, with technology transfer activities now underway. The company remains on track to file an IND for ERNA-101 in Q3 2026 and initiate first-in-human trials.
1. Completion of Process Development
Ernexa finalized process development activities for ERNA-101, establishing a robust manufacturing protocol for its lead cell therapy candidate. This milestone validates the underlying production approach and reduces technical risk ahead of clinical-grade manufacturing.
2. Transition to GMP Manufacturing and Technology Transfer
The ERNA-101 program has moved into Good Manufacturing Practice (GMP) production, and technology transfer efforts are underway to prepare external facilities for clinical-scale runs. These steps ensure regulatory compliance and operational readiness for generating trial material.
3. IND Submission on Track for Q3 2026
Ernexa is targeting an Investigational New Drug filing in the third quarter of 2026, which would set the stage for its first-in-human oncology study. Achieving IND clearance will mark the company's transition to a clinical-stage biotechnology enterprise.
